Michael Leuchten
Stock Analyst at Jefferies
(0.40)
# 4,411
Out of 4,996 analysts
507
Total ratings
49.4%
Success rate
-3.7%
Average return
Main Sectors:
Stocks Rated by Michael Leuchten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 17,500p | 12,430p | +40.79% | 106 | Sep 14, 2026 | |
| LON: GSK GSK plc | Reiterated: Buy | 2,500p | 1,886p | +32.56% | 48 | Sep 14, 2026 | |
| SWX: NOVN Novartis AG | Reiterated: Hold | CHF 110.00 | CHF 117.60 | -6.46% | 16 | Sep 7, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Reiterated: Hold | €46.00 | €49.31 | -6.71% | 96 | Aug 10, 2026 | |
| EPA: SAN Sanofi | Reiterated: Buy | €100.00 | €73.11 | +36.78% | 22 | Aug 7, 2026 | |
| SWX: ROP Roche Holding AG | Reiterated: Sell | CHF 230.00 | CHF 363.20 | -36.67% | 70 | Jun 8, 2026 | |
| GSK GSK plc | Reiterated: Buy | $56 → $67 | $49.71 | +34.98% | 4 | May 29, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Reiterated: Buy | €470.00 | €253.00 | n/a | 42 | Aug 21, 2023 | |
| ETR: MRK Merck KGaA | Reiterated: Buy | €208.00 | €132.95 | n/a | 40 | Aug 4, 2023 | |
| EPA: IPN Ipsen S.A. | Reiterated: Hold | €108.00 → €113.00 | €148.10 | n/a | 11 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €420.00 → €390.00 | €205.60 | n/a | 10 | Jun 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 2,650p | 3,580p | n/a | 1 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $38.17 | n/a | 20 | Jun 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | €400.00 | €205.50 | n/a | 6 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €83.00 → €80.00 | €39.60 | n/a | 4 | Nov 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €40.00 → €45.00 | €46.24 | n/a | 2 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | CHF 75.00 → CHF 85.00 | CHF 54.02 | n/a | 6 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $41.66 | n/a | 1 | May 12, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $142.71 | n/a | 2 | Apr 22, 2016 |
AstraZeneca PLC
Sep 14, 2026
Reiterated: Buy
Price Target: 17,500p
Current: 12,430p
Upside: +40.79%
GSK plc
Sep 14, 2026
Reiterated: Buy
Price Target: 2,500p
Current: 1,886p
Upside: +32.56%
Novartis AG
Sep 7, 2026
Reiterated: Hold
Price Target: CHF 110.00
Current: CHF 117.60
Upside: -6.46%
Bayer Aktiengesellschaft
Aug 10, 2026
Reiterated: Hold
Price Target: €46.00
Current: €49.31
Upside: -6.71%
Sanofi
Aug 7, 2026
Reiterated: Buy
Price Target: €100.00
Current: €73.11
Upside: +36.78%
Roche Holding AG
Jun 8, 2026
Reiterated: Sell
Price Target: CHF 230.00
Current: CHF 363.20
Upside: -36.67%
GSK plc
May 29, 2026
Reiterated: Buy
Price Target: $56 → $67
Current: $49.71
Upside: +34.98%
Sartorius Aktiengesellschaft
Aug 21, 2023
Reiterated: Buy
Price Target: €470.00
Current: €253.00
Upside: n/a
Merck KGaA
Aug 4, 2023
Reiterated: Buy
Price Target: €208.00
Current: €132.95
Upside: n/a
Ipsen S.A.
Jun 30, 2023
Reiterated: Hold
Price Target: €108.00 → €113.00
Current: €148.10
Upside: n/a
Jun 19, 2023
Reiterated: Buy
Price Target: €420.00 → €390.00
Current: €205.60
Upside: n/a
Oct 10, 2022
Reiterated: Buy
Price Target: 2,650p
Current: 3,580p
Upside: n/a
Jun 28, 2022
Downgraded: Sell
Price Target: n/a
Current: $38.17
Upside: n/a
Feb 28, 2022
Reiterated: Sell
Price Target: €400.00
Current: €205.50
Upside: n/a
Nov 4, 2021
Reiterated: Buy
Price Target: €83.00 → €80.00
Current: €39.60
Upside: n/a
Nov 2, 2021
Reiterated: Hold
Price Target: €40.00 → €45.00
Current: €46.24
Upside: n/a
Aug 23, 2021
Reiterated: Buy
Price Target: CHF 75.00 → CHF 85.00
Current: CHF 54.02
Upside: n/a
May 12, 2016
Upgraded: Buy
Price Target: n/a
Current: $41.66
Upside: n/a
Apr 22, 2016
Upgraded: Hold
Price Target: n/a
Current: $142.71
Upside: n/a